Parag Mallick bought $9,885 of NAUT
Chief Scientist at Nautilus Biotechnology, Inc.. 13,500 shares at an average of $0.73, traded May 8, 2025, filed May 12, 2025.
Score components
- +15RoleOfficer
- 0Trade size$10k at market
- -5Relative to holdingsUnder 1% of holdings (0.1%)
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001808805-25-000049, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 8, 2025 | POpen-market purchase Common Stock | +12,000 | $0.73 | $8,788 | 20,491,892 | May 12, 2025 |
| May 12, 2025 | POpen-market purchase Common Stock | +1,500 | $0.73 | $1,098 | 20,493,392 | May 12, 2025 |
Related signals
Other insiders at Nautilus Biotechnology, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | NAUTbuy Nautilus Biotechnology, Inc. | Kentaro Suzuki Chief Marketing Officer | $5,960 4,000 shares | - | |
| 44Moderate | Nautilus Biotechnology, Inc. | Sujal M Patel CEO, President, and Secretary | $136k 200,000 shares | +2% | |
| 29Weak | Nautilus Biotechnology, Inc. | Matthew B. Murphy General Counsel | $13k 20,000 shares | +37% | |
| 28Weak | NAUTbuy Nautilus Biotechnology, Inc. | Anna Mowry CFO and Treasurer | $11k 15,000 shares | +22% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.